Close Menu

NEW YORK – NeuMoDx Molecular said this week that its molecular assays for cytomegalovirus (CMV) and Epstein-Barr virus have received CE-IVD marking and are now commercially available in Europe and other locations that recognize the designation.

NeuMoDx's tests are designed for central laboratory use and run on the company's fully automated NeuMoDx 96 or 288 real-time PCR systems, which provide different levels of throughput. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.